Hot sale Cetrorelix - Travoprost CAS 157283-68-6 Assay 96.0%~102.0% API High Purity – Ruifu
Hot sale Cetrorelix - Travoprost CAS 157283-68-6 Assay 96.0%~102.0% API High Purity – Ruifu Detail:
Commercial Production with High Purity and Stable Quality
Chemical Name: Travoprost
CAS: 157283-68-6
Appearance: Colorless or Yellowish Oil
Assay: 96.0%~102.0% (anhydrous and solvent free basis)
Travoprost is used to treat glaucoma and ocular hypertension,is a potent and selective FP prostaglandin receptor agonist.
Chemical Name | Travoprost |
CAS Number | 157283-68-6 |
CAT Number | RF-API27 |
Stock Status | In Stock, Production Scale Up to Tons |
Molecular Formula | C26H35F3O6 |
Molecular Weight | 500.55 |
Brand | Ruifu Chemical |
Item | Specifications |
Appearance | Colorless or Yellowish Oil |
IR | Positive |
HPLC | Positive |
Specific Rotation [α]20D | +52° ~ +58° (20mg/ml, EtOH 365nm) |
Moisture (K.F) | ≤1.0% |
Related Substances | |
15-epi Diastereomer | ≤0.50% |
Epoxide Derivative | ≤0.40% |
Travoprost Free Acid | ≤0.50% |
5,6-trans-Travoprost | ≤1.0% |
Travoprost Methyl Ester | ≤0.50% |
15-Keto Derivative | ≤0.10% |
Any Other Impurity | ≤0.10% |
Total Other Impurities | ≤0.50% |
Residual Solvents | |
Acetonitrile | ≤0.04% |
Ethanol | ≤0.50% |
n-Hexane | ≤0.05% |
Assay | 96.0%~102.0% (anhydrous and solvent free basis) |
Test Standard | Enterprise Standard |
Usage | Active Pharmaceutical Ingredient (API) |
Package: Bottle, Barrel, 25kg/Barrel, or according to customer’s requirement.
Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.
Travoprost is used to treat glaucoma and ocular hypertension,is a potent and selective FP prostaglandin receptor agonist. Travoprost (Fluprostenol isopropyl ester), an isopropyl ester prodrug, is a high affinity, selective FP prostaglandin full receptor agonist.
Travoprost has the ocular hypotensive efficacy and has the potential for glaucoma and ocular hypertension. Travoprost was launched in the US as Travatan, an ophthalmic solution (0.004%) administered topically for the treatment of elevated intraocular hypertension (lOP) through open-angle glaucoma, a common optic neuropathy and a leading cause of blindness. Travoprost is the isopropyl ester of (+)-fluprostenol, a new prostaglandin derivative belonging to the PGF2α, analog class. This compound can be prepared in 8 steps from a bicyclic lactone aldehyde by a Wittig alkylidenation followed, after 2 ketonic reductions, by a lactol opening to prostenoic acid while protecting and deprotecting appropriately. Travoprost is a full agonist of FP receptors with a greater affinity than PGF2α, (K1 = 52 nM). Pharmacologic studies in rabbits treated daily for a week demonstrated a significant increase of the microvascular optic nerve head blood flow without significant alterations in the systemic flow. In several placebo-controlled clinical studies with hundreds of patients suffering from open-angle glaucoma or ocular hypertension, travoprost (1 to 4 pm daily) dose-dependently reduced lOP (by about 30% at 4 pm); it was shown equal or superior to latanoprost, another prostaglandin analog (5 pm daily) or the adrenergic ~-blocker timolol (500 pm bid). In addition, travoprost was safe and well tolerated with a low incidence of conjunctival hyperaemia.
Product detail pictures:
Related Product Guide:
The corporation keeps to the operation concept "scientific management, superior quality and performance primacy, consumer supreme for Hot sale Cetrorelix - Travoprost CAS 157283-68-6 Assay 96.0%~102.0% API High Purity – Ruifu , The product will supply to all over the world, such as: Brazil, Germany, Manchester, Our technical expertise, customer-friendly service, and specialized products make us/company name the first choice of customers and vendors. We are looking for your inquiry. Let's set up the cooperation right now!
By Ella from New Delhi - 2018.11.28 16:25
High Quality, High Efficiency, Creative and Integrity, worth having long-term cooperation! Looking forward to the future cooperation!
By Aaron from Canberra - 2017.08.18 11:04